Statins Do Not Reduce Atrial Fibrillation After Cardiac Valvular Surgery: A Single Centre Observational Study

Por Folkeringa, R. J., Tieleman, R. G., Maessen, J. G., Prins, M. H., Nieuwlaat, R., Crijns, H. J. G. M.
Publicado em 2010

Higher plasma high-mobility group box 1 levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12 year follow-up study

Por Nin, J. W. M., Ferreira, I., Schalkwijk, C. G., Jorsal, A., Prins, M. H., Parving, H.-H., Tarnow, L., Rossing, P., Stehouwer, C. D. A.
Publicado em 2012

Long term efficacy and safety of atorvastatin in the treatment of severe type III and combined dyslipidaemia

Por van Dam, M, Zwart, M, de Beer, F, Smelt, A H M, Prins, M H, Trip, M D, Havekes, L M, Lansberg, P J, Kastelein, J J P
Publicado em 2002

Feasibility of TEE-guided stroke risk assessment in atrial fibrillation—background, aims, design and baseline data of the TIARA pilot study

Por Dinh, T., Baur, L. H. B., Pisters, R., Kamp, O., Verheugt, F. W. A., Smeets, J. L. R. M., Cheriex, E. C., Tieleman, R. G., Prins, M. H., Crijns, H. J. G. M.
Publicado em 2011